drug
topiramate ER
Marketedupdated 3mo agoby LP Pharmaceutical (Xiamen) Co Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
Epilepsy
all catalysts(62)
approval · 62
Mar 27, 2009
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 27, 2009
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 27, 2009
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 13, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 28, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 23, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 23, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Oct 30, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 4, 2010
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jul 7, 2011
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jul 14, 2011
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jul 15, 2011
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Oct 22, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Oct 22, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 20, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 20, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 20, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 20, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 20, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Dec 1, 2014
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Dec 15, 2015
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Dec 15, 2015
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Dec 15, 2015
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Nov 5, 2021
approval
EPRONTIA (TOPIRAMATE) — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 10, 2022
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Oct 26, 2022
approval
EPRONTIA (TOPIRAMATE) — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 16, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 8, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 8, 2023
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 4, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 4, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 4, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 4, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Feb 22, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
May 17, 2024
approval
EPRONTIA (TOPIRAMATE) — FDA approval
topiramate ER
→
Jul 16, 2024
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 12, 2025
approval
EPRONTIA (TOPIRAMATE) — FDA approval
topiramate ER
→
Oct 7, 2025
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Dec 4, 2025
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 12, 2026
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 18, 2026
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Jan 27, 2026
approval
TOPIRAMATE — FDA approval
topiramate ER
→
Mar 6, 2026
approval
EPRONTIA (TOPIRAMATE) — FDA approval
topiramate ER
→
Trials studying topiramate ER
- phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase4A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- phase3A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
- phase3Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
- phase3A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
- phase4Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
- phase4A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 16, 2027
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (70)
- Aug 21, 2040method-of-use (U-3415)US 11433046
- Aug 21, 2040formulationUS 11633374
- Aug 21, 2040formulationUS 11826343
- Aug 21, 2040formulationUS 11911362
- Aug 21, 2040formulationUS 12290503
- Mar 19, 2033method-of-use (U-766)US 10363224
- Mar 19, 2033method-of-use (U-766)US 10363224
- Mar 19, 2033method-of-use (U-766)US 10363224
- Mar 19, 2033method-of-use (U-766)US 10363224
- Mar 19, 2033method-of-use (U-766)US 10363224
- Mar 19, 2033formulationUS 8652527
- Mar 19, 2033formulationUS 8652527
- Mar 19, 2033formulationUS 8652527
- Mar 19, 2033formulationUS 8652527
- Mar 19, 2033formulationUS 8652527
- Mar 19, 2033formulationUS 8889190
- Mar 19, 2033formulationUS 8889190
- Mar 19, 2033formulationUS 8889190
- Mar 19, 2033formulationUS 8889190
- Mar 19, 2033formulationUS 8889190
- Mar 19, 2033formulationUS 9101545
- Mar 19, 2033formulationUS 9101545
- Mar 19, 2033formulationUS 9101545
- Mar 19, 2033formulationUS 9101545
- Mar 19, 2033formulationUS 9101545
- Mar 19, 2033formulationUS 9555005
- Mar 19, 2033formulationUS 9555005
- Mar 19, 2033formulationUS 9555005
- Mar 19, 2033formulationUS 9555005
- Mar 19, 2033formulationUS 9555005
- Apr 4, 2028formulationUS 82985761.6y
- Apr 4, 2028formulationUS 82985761.6y
- Apr 4, 2028formulationUS 82985761.6y
- Apr 4, 2028formulationUS 82985761.6y
- Nov 16, 2027formulationUS 103147901.2y
- Nov 16, 2027formulationUS 103147901.2y
- Nov 16, 2027formulationUS 103147901.2y
- Nov 16, 2027formulationUS 103147901.2y
- Nov 16, 2027formulationUS 82985801.2y
- Nov 16, 2027formulationUS 82985801.2y
- Nov 16, 2027formulationUS 82985801.2y
- Nov 16, 2027formulationUS 82985801.2y
- Nov 16, 2027formulationUS 86636831.2y
- Nov 16, 2027formulationUS 86636831.2y
- Nov 16, 2027formulationUS 86636831.2y
- Nov 16, 2027formulationUS 86636831.2y
- Nov 16, 2027formulationUS 88772481.2y
- Nov 16, 2027formulationUS 88772481.2y
- Nov 16, 2027formulationUS 88772481.2y
- Nov 16, 2027formulationUS 88772481.2y
- Nov 16, 2027method-of-use (U-106)US 88891911.2y
- Nov 16, 2027method-of-use (U-1992)US 88891911.2y
- Nov 16, 2027method-of-use (U-1992)US 88891911.2y
- Nov 16, 2027method-of-use (U-1992)US 88891911.2y
- Nov 16, 2027formulationUS 89929891.2y
- Nov 16, 2027formulationUS 89929891.2y
- Nov 16, 2027formulationUS 89929891.2y
- Nov 16, 2027formulationUS 89929891.2y
- Nov 16, 2027formulationUS 95499401.2y
- Nov 16, 2027formulationUS 95499401.2y
- Nov 16, 2027formulationUS 95499401.2y
- Nov 16, 2027formulationUS 95499401.2y
- Nov 16, 2027formulationUS 95550041.2y
- Nov 16, 2027formulationUS 95550041.2y
- Nov 16, 2027formulationUS 95550041.2y
- Nov 16, 2027formulationUS 95550041.2y
- Nov 16, 2027formulationUS 96229831.2y
- Nov 16, 2027formulationUS 96229831.2y
- Nov 16, 2027formulationUS 96229831.2y
- Nov 16, 2027formulationUS 96229831.2y
FDA exclusivities (2)
- Feb 1, 2026CGTCGT
- Jan 5, 2026PCPC
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that